Skip to content
CG

Centuple Global

531099 BSE
₹33.89

Close ·

P/E
15.13
View as Markdown
MCP
Close 4 Nov 2026 ₹33.89 −38.50 −53.2% 1Y
Start ₹72.39

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
15.00%
Debt to Equity
0.30
EPS (TTM)
₹2.24
Book Value
₹3.78
Market Cap
—
P/E (TTM)
15.13
P/B
8.97
ROE
12.70%
Dividend Yield
0.00%
EBITDA
₹2.30 Cr
52W High
₹144.40
52W Low
₹28.42

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

42 Weak

Data confidence 98/100

Category scores

Quality
25
Poor
Returns, margins, earnings quality 22% weight
Valuation
43
Weak
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
21
Poor
Solvency, leverage, coverage 9% weight
Momentum
14
Poor
Trend strength, vol-adjusted 12% weight
Ownership
56
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Stock is trading at 0.77 times its book value
  • Company's median sales growth is 26.2% of last 10 years
  • Company's working capital requirements have reduced from 182 days to 14.7 days

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 12.3% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 215 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1162
OscillatorsBullish162
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
48.48
Neutral
MACD (12,26,9)
0.34
Bearish
SMA (50)
34.10
Bearish
SMA (200)
52.07
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YZero base
5YZero base
3Y+731.07%
1YZero base
TTMTiny base

Net profit

Net profit growth by window
10YZero base
5YZero base
3YZero base
1YZero base
TTMTiny base

Operating cash flow

Operating cash flow growth by window
10YTurned negative
5YTurned negative
3YTurned negative
1YTurned negative
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YNo sales
5YNo sales
3Y+0.35 pp
1YNo sales
TTM−0.55 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹2.00 Cr
Mar 2019₹1.00 Cr
Mar 2020₹1.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹2.00 Cr
Mar 2023₹1.00 Cr
Mar 2024₹1.00 Cr
Mar 2025₹0.00 Cr
Mar 2026₹574 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹0.00 Cr
Mar 2026₹2.00 Cr

Quarterly Results

₹ Cr
531099 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0.2
0.29
0.17
0.47
0.1
0.05
0.1
0.25
11.71
109
174
279
0
Expenses
0.25
0.03
0.11
0.71
0.07
0.08
0.14
0.16
11.62
107
173
280
0.18
Operating Profit
−0.05
0.26
0.06
−0.24
0.03
−0.03
−0.04
0.09
0.09
1.8
0.77
−0.37
−0.18
OPM %
−25%
89.66%
35.29%
−51.06%
30%
−60%
−40%
36%
0.77%
1.66%
0.44%
−0.13%
—
Other Income
0
0
0
0
0
0
0.02
−0.02
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
−0.05
0.26
0.06
−0.24
0.03
−0.03
−0.02
0.07
0.09
1.8
0.77
−0.37
−0.18
Tax %
0%
0%
0%
−4.17%
0%
33.33%
0%
0%
0%
26.11%
25.97%
27.03%
0%
Net Profit
−0.05
0.26
0.06
−0.23
0.02
−0.04
−0.02
0.06
0.09
1.32
0.57
−0.48
−0.18
EPS (₹)
−0.09
0.48
0.11
−0.42
0.04
−0.07
−0.04
0.11
0.16
2.41
1.04
−0.88
−0.33

Profit & Loss

₹ Cr
531099 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
0
0
2
1
1
0
2
1
1
0
574
562
Expenses
0
0
0
2
1
1
0
2
1
1
0
572
560
Operating Profit
0
0
0
0
0
0
0
0
0
0
0
2
2
OPM %
—
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
−1.3%
−31%
2%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
−1%
−7%
2.6%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
0.4%
0.4%
Other Income
−3
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
−3
0
0
0
0
0
0
0
0
0
0
2
2
Tax %
0%
0%
0%
0%
0%
20%
0%
50%
0%
−50%
40%
34%
—
Net Profit
−3
0
0
0
0
0
0
0
0
0
0
2
1
EPS (₹)
−5.61
−0.02
0.05
−0.29
−0.02
0.05
0.02
−0.07
−0.15
0.05
0.05
2.76
2.24
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
531099 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
5
5
5
5
Reserves
−5
−5
−5
−5
−5
−5
−5
−5
−5
−5
−5
18
Borrowings
0
0
0
0
0
0
0
0
0
0
0
7
Other Liabilities
0
0
0
0
0
0
0
0
0
0
0
313
Total Liabilities
0
0
1
1
1
1
1
1
1
1
1
343
Fixed Assets
0
0
0
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
0
0
1
1
1
1
1
1
1
1
1
343
Total Assets
0
0
1
1
1
1
1
1
1
1
1
343

Cash Flow

₹ Cr
531099 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
0
0
0
0
0
1
0
0
0
0
−28
Investing
0
0
0
0
0
0
0
0
0
0
0
0
Financing
0
0
0
0
0
0
0
0
0
0
0
28
Net Cash Flow
0
0
0
0
0
0
1
0
0
0
0
0
Free Cash Flow
0
0
0
0
0
0
1
0
0
0
0
−28
CFO/OP
114
100
133
−600
17
650
5,200
2,450
−12
0
190
−1,223

Ratios

531099 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
—
—
54
179
107
—
122
135
229
—
215
Inventory Days
—
—
—
0
0
0
—
0
—
—
—
1
Days Payable
—
—
—
—
—
—
—
—
—
—
—
197
Cash Conversion Cycle
—
—
—
54
179
107
—
122
135
229
—
19
Working Capital Days
—
—
—
36
260
221
—
98
129
145
—
15
ROCE %
−3%
−3%
7%
25%
−31%
3%
2%
−3%
−13%
3%
17%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Centuple Global insights

57 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 71.92%
  • FIIs 19.14%
  • Others 8.93%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Centuple Global

What does Centuple Global Ltd do?
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy
Where is Centuple Global Ltd (CENTUPLE) listed?
Centuple Global Ltd trades under code 531099 on the BSE.
Which sector does Centuple Global Ltd belong to?
Centuple Global Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Centuple Global Ltd?
Centuple Global Ltd trades at a PE ratio of 15.13 as of 4 Nov 2026, on earnings per share of ₹2.24, against a book value of ₹3.78 per share.
What is the 52-week high and low of Centuple Global Ltd?
Over the last 52 weeks Centuple Global Ltd has traded between ₹28.42 and ₹144.4 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Centuple Global Ltd?
Centuple Global Ltd reported a return on equity of 12.70%. Its debt-to-equity ratio is 0.30.

Company Information

Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy

Website rubramed.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531099.md for Centuple Global Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month